Scarica l'app Stockscreener
761.85
1.98%
-15.40
Dopo l'orario di chiusura:
761.54
-0.31
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Tritonpoint Wealth LLC Sells 1,938 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC - MarketBeat
Regeneron’s EYLEA HD Label Update Shifts Retinal Care And Competition - simplywall.st
Regeneron Pharma (REGN) shares up after Jim Cramer called it a good stock - MSN
Regeneron Pharmaceuticals Inc (REGN) SEC filings - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Allspring Global Investments Boosts Stake in Regeneron Pharmaceuticals - National Today
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc - GuruFocus
Regeneron (REGN) director Ryan sells $77,727 in stock By Investing.com - Investing.com South Africa
Regeneron Pharmaceuticals Inc (RGO.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Regeneron (REGN) director Ryan sells $77,727 in stock - Investing.com
Small Rule 10b5-1 sale by Regeneron (REGN) director Arthur F. Ryan - Stock Titan
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance Australia
Regeneron Secures Two FDA Approvals in One Day: Does the Math Support an Above $1,200 Target? - TIKR.com
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation - FinancialContent
The Bull Case For Regeneron (REGN) Could Change Following New Dupixent BP Approval In JapanLearn Why - simplywall.st
Aberdeen Group Boosts Regeneron Pharmaceuticals Holdings - National Today
Aberdeen Group plc Has $124.84 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Approves Extension of Dosing Intervals for Regeneron's Eylea HD - VisionMonday.com
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
FDA approves extended dosing for Regeneron’s EYLEA HD treatment By Investing.com - Investing.com Australia
Regeneron partners with TriNetX for health data access - Investing.com
Regeneron Pharmaceuticals announced that, as part of their strategic partnership, the company will invest up to 200 million dollars in Trinetx. - Bitget
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN34.SA) company profile and facts - Yahoo Finance Singapore
Regeneron says it expects to avoid new US pharma tariffs - Reuters
FDA Expands Dosing Flexibility for Regeneron's EYLEA HD - GuruFocus
FDA approves extended dosing for Regeneron’s EYLEA HD treatment - Investing.com
FDA lets some EYLEA HD patients cut eye injections to 2 or 3 a year - Stock Titan
Ophthalmology Drugs Market: Current Landscape and Future Outlook - Barchart
Moody Lynn & Lieberson LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN
AVIP BlackRock Balanced Allocation Portfolio's Regeneron Pharmaceuticals Inc(REGN) Holding History - GuruFocus
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
BMO Autocallable Notes Linked to Regeneron (NASDAQ: REGN) — US$270K - Stock Titan
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Japan’s Approval Of Dupixent For Bullous Pemphigoid - Yahoo Finance
Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment - The Globe and Mail
Piper Sandler Rates Regeneron Pharmaceuticals (REGN) as Overweig - GuruFocus
Piper Sandler Rates Regeneron Pharmaceuticals (REGN) as Overweight | REGN Stock News - GuruFocus
Truist Securities Updates Regeneron Pharmaceuticals (REGN) Price Target | REGN Stock News - GuruFocus
Truist Financial Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron a new overweight at Piper on Dupixent, pipeline - Seeking Alpha
Truist cuts Regeneron stock price target on biosimilar concerns - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Piper Sandler - MarketBeat
Piper Sandler initiates Regeneron stock with Overweight rating - Investing.com
Is It Time To Reassess Regeneron (REGN) After Its Mixed Share Price Performance? - simplywall.st
Regeneron stock gets a new roadmap investors can track in 2026 - MSN
Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena - theglobeandmail.com
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies - theglobeandmail.com
Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock - Insider Monkey
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Japan’s New Dupixent Approval - simplywall.st
1.91%
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):